Fintel reports that on May 11, 2023, JMP Securities reiterated coverage of Altimmune (NASDAQ:ALT) with a Market Outperform recommendation.
Analyst Price Forecast Suggests 437.65% Upside
As of May 11, 2023, the average one-year price target for Altimmune is 26.78. The forecasts range from a low of 6.06 to a high of $52.50. The average price target represents an increase of 437.65% from its latest reported closing price of 4.98.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Altimmune is 0MM. The projected annual non-GAAP EPS is -2.18.
What is the Fund Sentiment?
There are 211 funds or institutions reporting positions in Altimmune. This is an increase of 9 owner(s) or 4.46% in the last quarter. Average portfolio weight of all funds dedicated to ALT is 0.22%, an increase of 51.18%. Total shares owned by institutions decreased in the last three months by 4.70% to 51,511K shares. 
The put/call ratio of ALT is 0.16, indicating a bullish outlook.
What are Other Shareholders Doing?
XBI - SPDR(R) S&P(R) Biotech ETF holds 5,785K shares representing 11.74% ownership of the company. In it's prior filing, the firm reported owning 3,279K shares, representing an increase of 43.32%. The firm increased its portfolio allocation in ALT by 93.41% over the last quarter.
Avidity Partners Management holds 3,990K shares representing 8.10% ownership of the company. In it's prior filing, the firm reported owning 2,684K shares, representing an increase of 32.73%. The firm increased its portfolio allocation in ALT by 104.06% over the last quarter.
Janus Henderson Group holds 3,834K shares representing 7.78% ownership of the company. In it's prior filing, the firm reported owning 4,122K shares, representing a decrease of 7.52%. The firm increased its portfolio allocation in ALT by 14.25% over the last quarter.
Nuveen Asset Management holds 3,266K shares representing 6.63% ownership of the company. In it's prior filing, the firm reported owning 3,214K shares, representing an increase of 1.59%. The firm increased its portfolio allocation in ALT by 25.24% over the last quarter.
Tang Capital Management holds 2,700K shares representing 5.48% ownership of the company. In it's prior filing, the firm reported owning 2,600K shares, representing an increase of 3.70%. The firm increased its portfolio allocation in ALT by 58.47% over the last quarter.
Altimmune Background Information
(This description is provided by the company.)
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™).
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
